FMP

FMP

Enter

BHVN - Biohaven Pharmaceuti...

Financial Summary of Biohaven Pharmaceutical Holding Company Ltd.(BHVN), Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candida

photo-url-https://financialmodelingprep.com/image-stock/BHVN.png

Biohaven Pharmaceutical Holding Company Ltd.

BHVN

NYSE

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

36.51 USD

-1.48 (-4.05%)

About

ceo

Dr. Vladimir Coric M.D.

sector

Healthcare

industry

Biotechnology

website

https://www.biohavenpharma.com

exchange

NYSE

Description

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amy...

CIK

0001689813

ISIN

VGG1110E1079

CUSIP

G11196105

Address

215 Church Street

Phone

203 404 0410

Country

US

Employee

239

IPO Date

Sep 23, 2022

Summary

CIK

0001689813

Exchange

NYSE

Industry

Biotechnology

Sector

Healthcare

CUSIP

G11196105

ISIN

VGG1110E1079

Country

US

Price

36.51

Beta

4.17

Volume Avg.

1.42M

Market Cap

3.22B

Shares

-

52-Week

14.96-62.21

DCF

3.07

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-5.29

P/B

-

Website

https://www.biohavenpharma.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest BHVN News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep